Education
About Us
Working with TipRanks
Follow Us
Aethlon Medical Inc (AEMD)
NASDAQ:AEMD
Earnings Data
Report Date
Jun 25, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-2.01Last Year’s EPS
-32.2Same Quarter Last Year
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call conveyed meaningful operational and scientific progress—most notably favorable safety signals in the Australian oncology trial, expansion of EV research with multiple preclinical publications, a potential pathway to simplify delivery (SLAMB), and a sizable 27% reduction in nine-month operating expenses. Offsetting these positives are near-term financial constraints and mixed quarterly financials: a $7.0 million cash balance that may limit runway, a quarterly operating expense increase of 13.6% and higher operating loss, reduced interest income, and program/timing uncertainties (DSMB decisions and SLAMB regulatory/technical work still preliminary). Overall, the update reflects constructive clinical and R&D momentum but with clear near-term financial and operational risks that leave the outlook balanced.Company Guidance
Australian oncology trial advancing with favorable safety signals
Cohort 1 completed (3 participants received a single Hemopurifier treatment) with no device-related serious adverse events or dose-limiting toxicities; directional improvements observed in extracellular vesicle (EV) counts and immune cell numbers. Cohort 2: two participants have completed 2 HP treatments and a third patient is enrolled and expected to be treated by end of February; independent DSMB review targeted for late March to recommend advancement to Cohort 3 or additional patients.
Expanded EV research and potential multi-indication pipeline
Ongoing expansion of extracellular vesicle (EV) research supporting Hemopurifier as a potential multi-indication therapeutic. Published trial design in BMJ Open; Long COVID preclinical data show GNA affinity resin binds EVs and decreases microRNAs linked to immune dysregulation (preprint on bioRxiv); prior data show platelet-derived EV removal (bioRxiv). Company exploring additional EV cargo (e.g., viral particles) and plans disease-plasma studies to broaden indications.
Workstream toward simplified delivery (SLAMB) could expand clinical settings
Under a Material Transfer Agreement with Stavro to study compatibility with SLAMB system (single small-lumen catheter and simplified pump). If compatible, could shift Hemopurifier treatments from dialysis units with large double-lumen catheters and dialysis machines to oncology units or infusion centers using PICC-like catheters, reducing invasiveness and operational complexity.
Meaningful year-to-date operating expense reduction
Consolidated operating expenses for the nine months ended December 31, 2025 decreased to $5.36 million from $7.34 million year-ago, a reduction of $1.98 million or 27%, driven by lower payroll, general & administrative costs and professional fees—reflecting disciplined cost management.
Enrollment momentum via Trialfacts and Dedicated
Contracting marketing and prescreening partners (Trialfacts for online advertising; Dedicated for phone prescreening) has produced an uptick in interested potential participants and a referral pool for investigative sites, providing a queue of candidates that could accelerate enrollment into Cohort 3 once approved by the DSMB.
AEMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AEMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 12, 2026 | $1.98 | $1.96 | -1.01% |
Nov 12, 2025 | $4.20 | $4.74 | +12.86% |
Aug 13, 2025 | $12.30 | $11.70 | -4.88% |
Jun 26, 2025 | $19.40 | $12.50 | -35.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aethlon Medical Inc (AEMD) report earnings?
Aethlon Medical Inc (AEMD) is schdueled to report earning on Jun 25, 2026, After Close (Confirmed).
What is Aethlon Medical Inc (AEMD) earnings time?
Aethlon Medical Inc (AEMD) earnings time is at Jun 25, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AEMD EPS forecast?
AEMD EPS forecast for the fiscal quarter 2026 (Q4) is -2.01.